ProjectTargeting RNA as an approach for treating retinal disease - Expression of RNA based TrkB-aptamers for the…
Basic data
Title:
Targeting RNA as an approach for treating retinal disease - Expression of RNA based TrkB-aptamers for the treatment of age-related macular degeneration
Duration:
01/02/2023 to 31/01/2027
Abstract / short description:
The present DN “Targeting RNA as an approach for treating retinal disease” (RETORNA) aims to treat RD by using
RNA therapy. Among the research objectives, we will study different types of RNA that are expressed in retinal cells. By
observing bioinformatic models, cell and tissue cultures, animal models, and human patients, we will be able to create
RNA profiles for different RD. This screening will identify several targets that will be used as therapeutic approaches.
Then, selected RNAs will be used to treat different RD, such as macular degeneration and retinitis pigmentosa.
Furthermore, the potential economic and social impact of such strategies upon European countries will be studied, and
the possibility of commercialization will be assessed.
The aim of this individual project is to demonstrate that TrkB signalling activation via highly specific aptamers directly expressed have a therapeutic
effect for AMD.
RNA therapy. Among the research objectives, we will study different types of RNA that are expressed in retinal cells. By
observing bioinformatic models, cell and tissue cultures, animal models, and human patients, we will be able to create
RNA profiles for different RD. This screening will identify several targets that will be used as therapeutic approaches.
Then, selected RNAs will be used to treat different RD, such as macular degeneration and retinitis pigmentosa.
Furthermore, the potential economic and social impact of such strategies upon European countries will be studied, and
the possibility of commercialization will be assessed.
The aim of this individual project is to demonstrate that TrkB signalling activation via highly specific aptamers directly expressed have a therapeutic
effect for AMD.
Involved staff
Managers
Center for Ophthalmology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Local organizational units
University Eye Hospital
Center for Ophthalmology
Hospitals and clinical institutes, Faculty of Medicine
Hospitals and clinical institutes, Faculty of Medicine
Funders
Brüssel, Belgium